key: cord-0972606-ut0evhls
authors: Gandotra, Akash; Mehtani, Rohit; Premkumar, Madhumita; Duseja, Ajay; De, Arka; Mallik, Nabhajit; Durgadevi, S.; Das, Ashim; Kalra, Naveen
title: Invasive Pulmonary Aspergillosis and Tuberculosis complicated by Hemophagocytic Lymphohistiocytosis - Sequelae of COVID-19 in a Liver Transplant Recipient
date: 2021-12-08
journal: J Clin Exp Hepatol
DOI: 10.1016/j.jceh.2021.12.002
sha: 24563ae9fd0b5466afc00876a133b3ec151b65ac
doc_id: 972606
cord_uid: ut0evhls

Liver transplant recipients are at an increased risk of opportunistic infections due to use of immunosuppression. Coronavirus disease of 2019 (COVID-19) increases the risk of these infections further due to associated immune dysfunction and use of high dose steroids. We present a case of liver transplant recipient who developed disseminated tuberculosis and invasive pulmonary aspergillosis complicated by acquired hemophagocytic lymphohistiocytosis after recovering from severe COVID-19.

Liver transplant recipients are associated with adverse outcomes after infection with coronavirus disease of 2019 (COVID-19) 1 . Use of high dose immunosuppression has also led to a rise in cases of invasive aspergillosis worldwide 2 . We describe a case highlighting the role of post-transplant immunosuppression and COVID-19 in causing reactivation of tuberculosis and invasive pulmonary aspergillosis, complicated by acquired Hemophagocytic Lymphohistiocytosis (HLH).

We report the case of a 47-year-old gentleman who underwent living donor liver transplant in 2018 for chronic hepatitis B and hepatitis C co-infection related decompensated cirrhosis and hepatocellular carcinoma (HCC) within Milan criteria. Post-Transplant his liver functions were stable on maintenance immunosuppression with Sirolimus 2 mg twice a day. He had early recurrence of HCC three months post-transplant which was managed with a combination of lenvatinib and loco-regional therapy in the form of 2 sessions of microwave ablation (MWA) and 2 sessions of doxorubicin drug eluting bead trans-arterial chemoembolization (DEB-TACE) and was in remission since the last 18 months as determined by serial imaging as per mRECIST (modified response evaluation criteria in solid tumors) criteria. The patient developed new onset diabetes after transplant (NODAT) a year ago and was on metformin therapy. The patient tested positive for severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) in the month of March 2021 after complaining of two weeks of fever and dry cough.

He had not been vaccinated for coronavirus disease of 2019 (COVID-19) at the time of infection. He was found to have moderate COVID-19 due to presence of respiratory distress for which he required admission in outside hospital for 3 days where his immunosuppression was switched from sirolimus (4 mg per day) to oral prednisolone (40 mg per day for a week, followed by 10 mg daily). He also received low molecular heparin for 7 days. Ten days later, he complained of progressive shortness of breath along with high grade fever, and fatigue. At this admission, he tested negative for COVID-19 on the SARS-CoV-2 reverse transcriptase polymerase chain reaction (RT-PCR) report. On examination, he had tachycardia, tachypnea, and hypoxemia, with chest crepitations, and a palpable spleen. He required high flow oxygen by Venturi-mask with an FiO2 of 60%. Laboratory investigations were suggestive of pancytopenia, acute kidney injury (AKI), elevated liver enzymes and elevated serum procalcitonin ( Table 1) . Ultrasound of the abdomen revealed splenomegaly with a spleen size of 17 cm. In view of fever, pancytopenia, splenomegaly, and calculated H-score being 306 (Table 2) He was managed with intravenous immune globulin for HLH, liposomal Amphotericin B and anti-tubercular therapy (ATT). In view of elevated procalcitonin, AKI and multi organ involvement, he received intensive fluid management along with broad spectrum antibiotic coverage with intravenous meropenem. Liposomal amphotericin B was switched to oral Posaconazole after 3 weeks. AKI was likely pre-renal as there was no proteinuria and it improved with fluid resuscitation. He improved clinically with resolution of fever, hypoxia and pancytopenia. He was switched again to a sirolimus based immunosuppression, with complete resolution of cytopenia after 7 days of therapy (Table 1) . A repeat positron emission tomographic scan revealed resolution of chest nodules, and old neoplastic lesions with post TACE/ ablation changes in the graft liver. The patient has completely recovered and is on modified antitubercular therapy and tapering steroid/ sirolimus immunosuppression.

Infectious complications remain important preventable causes of morbidity and mortality among liver transplant patients. Opportunistic infections including mycobacterium tuberculosis infection and invasive fungal infections occur most commonly 1-6 months post-transplant when immunosuppression is at its peak 3 . A systematic review showed that liver transplant recipients have 18-fold increased risk of active tuberculosis infection than general population and 4 times increased mortality 4 . A systematic review and meta-analysis demonstrated dyspnoea on presentation, hypertension, diabetes mellitus, use of corticosteroids and age 60 years or older to be significantly associated with increased mortality 5 . Initially liver transplant recipients were considered to be at increased risk of adverse outcomes due to COVID-19, however, a recent systematic review and meta-analysis demonstrated similar outcomes in liver transplant recipients as non-transplant recipients 6 .

This case shows the tricky management of post COVID-19 sequelae in a liver transplant recipient who was on immunosuppression, multikinase inhibitor therapy, with background diabetes and HCC in remission. In the index case, sirolimus was switched to prednisolone at the time of diagnosis of COVID-19. Theoretically, Sirolimus is expected to reduce infection in high-risk populations and severity of COVID-19 7 , however, the evidence for the same is lacking. The proven benefit of steroids in improving mortality in patients with severe COVID-19 8 could have led to the decision to switch to prednisolone for immunosuppression in the index case. However, use of steroids for COVID pneumonia resulted in reactivation of tuberculosis, superadded invasive pulmonary aspergillosis, and granulomatous inflammation in the marrow leading to secondary HLH. Diagnosis of tuberculosis was based on presence of acid-fast bacilli in the sputum, however, culture for mycobacteria tuberculosis or molecular assays were not done. Although, alkaline phosphatase was markedly raised in the index case, a liver biopsy to demonstrate granulomatous involvement of liver was not performed as the patient was started treatment for both disseminated TB and HLH and no additional information was expected from a liver biopsy. A diagnosis of probable invasive pulmonary aspergillosis (IPA) was as per the Infectious Diseases Society of America (IDSA) guidelines with CT imaging, aspergillus culture positivity in sputum sample and raised BDG/GM as biomarkers 9 . Broncho-alveolar lavage or lung biopsy was not done due to the poor general condition of the patient.

Secondary hemophagocytic lymphohistiocytosis (sHLH) is a life-threatening syndrome of excessive immune activation that results in a hyperinflammatory state and consequently tissue destruction. Acquired HLH after COVID-19 infection is seen in about 6.3% cases and is associated with a high mortality 10 . Majority cases of HLH occur during the active phase of the disease, however, recent reports have highlighted development of HLH even after the patient has recovered from COVID-19 11, 12 , as was seen in our index case. Cardinal features of sHLH include unremitting fever, cytopenias, and hyperferritinemia; pulmonary involvement (including ARDS) occurs in approximately 50% of patients 13 . Treatment options include steroids, immunoglobulins, and interleukin inhibitors 14 . High suspicion is needed to diagnose sHLH. Our patient was successfully managed by timely intravenous immunoglobulin (IVIg) with biopsy confirming the presence of both hemophagocytosis and granulomatous inflammation. 

Clinical Presentation, Treatment, and Mortality Rate in Liver Transplant Recipients With Coronavirus Disease 2019: A Systematic Review and Quantitative Analysis

Mortality in critically ill patients with coronavirus disease 2019-associated pulmonary aspergillosis: A systematic review and metaanalysis

Infections in liver transplant recipients

Tuberculosis in liver transplant recipients: a systematic review and meta-analysis of individual patient data

Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19

Impact of COVID-19 on liver transplant recipients-A systematic review and meta-analysis

The potential of rapalogs to enhance resilience against SARS-CoV-2 infection and reduce the severity of COVID-19

Infection-associated Hemophagocytic Syndrome in Critically Ill Patients with COVID-19

Secondary hemophagocytic lymphohistiocytosis in post-COVID-19 patients: a report of two cases

Hemophagocytic lymphohistiocytosis, a new cause of death during 'post-acute COVID-19 syndrome?' A case report

HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis

Current Updates on Classification, Diagnosis and Treatment of Hemophagocytic Lymphohistiocytosis (HLH)

Reactivation TB with severe COVID-19

Reactivation of pulmonary tuberculosis in a patient with COVID-19. Infectious Diseases in Clinical Practice

The authors have no funding sources or conflicts of interests to declare.J o u r n a l P r e -p r o o f